JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Serum albumin as an independent predictor of early mortality in metastatic gastric cancer
Abstract
Aims: This study aims to evaluate the prognostic value of baseline clinical and laboratory parameters in predicting six-month early mortality among patients with metastatic gastric cancer.
Methods: In this retrospective observational study, 91 patients diagnosed with metastatic (Stage IV) gastric adenocarcinoma between January 2016 and January 2026 were evaluated. The primary endpoint was mortality within the first six months following diagnosis. Univariate and multivariate logistic regression analyses were utilized to identify early mortality predictors, while receiver operating characteristic (ROC) curve analysis evaluated the predictive performance of serum albumin.
Results: During the follow-up period, 29 patients (31.9%) died within the first six months. Patients experiencing early mortality presented with significantly lower baseline serum albumin levels (28.6 ± 7.7 vs 36.7 ± 5.6 g/L, p < 0.001) and higher C-reactive protein (CRP) levels. Although the lack of response to first-line chemotherapy, serum albumin, and CRP were significant in the univariate analysis, multivariate logistic regression revealed that baseline serum albumin level (p<0.001, OR: 0.84) was the sole independent risk factor predicting six-month mortality. Furthermore, ROC analysis determined an optimal cut-off value of ?35 g/L for albumin, which demonstrated an 80% sensitivity and a 53% specificity (AUC: 0.80).
Conclusion: Pre-treatment serum albumin level serves as an independent, highly accessible, and powerful predictor of six-month early mortality in patients with metastatic gastric cancer. This routine parameter effectively reflects a patient's inflammatory status and physiological reserve, aiding in the identification of high-risk patients in clinical practice.

Keywords : Gastric neoplasms, prognosis, survival analysis, biomarkers, nutritional status

Download Article
Ethical Statement

<p>This study was approved by the Non-interventional Clinical Researches Ethics Committee at the Van Y&uuml;z&uuml;nc&uuml; Yıl University (Date: 17.04.2026, Decision No: 2026/04-04).</p>

Informed Consent

<p>This retrospective study used pre-existing anonymized patient data. No additional intervention was performed, and there was no direct patient contact. The study was approved by the Ethics Committee, and the requirement for written informed consent was waived by the ethics committee.</p>

Author Contributions

<p>Concept: MK, M&Uuml;; Design: MK; Control: M&Uuml;; Resources: MK; Materials: MK, M&Uuml;; Data Collection and/or Processing: M&Uuml;; Analysis and/or Interpretation: MK; Literature Review: M&Uuml;; Writing the Article: MK; Critical Review: MK, M&Uuml;.</p>

Conflict of Interest

<p>The authors declare no conflicts of interest related to this study.</p>

Financial Disclosure

<p>The authors received no financial support for the conduct or publication of this research.</p>


1. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279-287. doi:10.1016/S1470-2045(08)70072-X
2. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-592. doi:10.1097/00000658-199321850-00002
3. Feng Y, Guo K, Jin H, et al. A predictive nomogram for early mortality in Stage IV gastric cancer. Med Sci Monit. 2020;26:e923931. doi:10.12659/MSM.923931
4. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064. doi:10.1002/14651858.CD004064.pub4
5. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395-2403. doi:10.1200/JCO.2004.08.154
6. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540. doi:10.1016/j.ctrv.2012.08.003
7. Wei C, Yu Z, Wang G, et al. Low pretreatment albumin-to-globulin ratio predicts poor prognosis in gastric cancer: insight from a meta-analysis. Front Oncol. 2021;10:623046. doi:10.3389/fonc.2020.623046
8. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi:10.1186/1475-2891-9-69
9. Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381-389. doi:10.1245/s10434-006-9093-x
10. Almasaudi AS, Dolan RD, Edwards CA, et al. Hypoalbuminemia reflects nutritional risk, body composition and systemic inflammation and is independently associated with survival in patients with colorectal cancer. Cancers (Basel). 2020;12(7):1986. doi:10.3390/cancers12071986
11. Mao MJ, Wei XL, Sheng H, et al. Clinical significance of preoperative albumin and globulin ratio in patients with gastric cancer undergoing treatment. BioMed Res Int. 2017;2017:3083267. doi:10.1155/2017/3083267
12. Crumley AB, Stuart RC, McKernan M, et al. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34(10):2393-2398. doi:10.1007/s00268-010-0641-y
13. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3): 223-226. doi:10.1097/MCO.0b013e32832a7902
14. Zhang S, Li JZ, Du T, et al. The Modified Glasgow Prognostic Score predicts survival in gastric cancer patients with normal CEA and CA19-9. Can J Gastroenterol Hepatol. 2022;2022:3953004. doi:10.1155/2022/3953004
15. Moriyama J, Oshima Y, Nanami T, et al. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today. 2021;51(10):1638-1648. doi:10.1007/s00595-021-02248-y
16. Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181(1):16-19. doi:10.1016/s0002-9610(00)00549-3
17. Kim EY, Lee JW, Yoo HM, et al. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol. 2015;22(13):4363-4370. doi:10.1245/s10434-015-4518-z
18. Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672. doi:10.1186/s12885-019-5903-y
19. Cheon SH, Rha SY, Jeung HC, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146-1153. doi:10.1093/annonc/mdn026
Article available in :
Volume 4, Issue 4, 2026
Page : 146-151
https://doi.org/10.51271/JCHOR-0099
Article Information
Received : 02 Jul 2026
Accepted : 08 Sep 2026
Published : 13 Nov 2026
Corresponding Author :

Mahmut Kara: Department of Medical Oncology, Sinop Atatürk State Hospital, Sinop, Turkiye

[email protected]
Citation : Kara M, Ürün M. Serum albumin as an independent predictor of early mortality in metastatic gastric cancer. J Curr Hematol Oncol Res. 2026;4(4):146-151. doi:10.51271/JCHOR-0099

Read: 6
Download : 4
Cited: 0
_Footer